reboxetine has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Caso, JR; García-Bueno, B; Gómez-Garre, D; González-Prieto, M; Gutiérrez, IL; Leza, JC; Madrigal, JLM; Ortega-Hernández, A | 1 |
| Caso, JR; García-Bueno, B; González-Prieto, M; Gutiérrez, IL; Leza, JC; Madrigal, JLM | 1 |
2 other study(ies) available for reboxetine and Alzheimer Disease
| Article | Year |
|---|---|
Microglial CX3CR1 production increases in Alzheimer's disease and is regulated by noradrenaline.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; CX3C Chemokine Receptor 1; Mice; Microglia; Norepinephrine; Rats; Reboxetine | 2021 |
Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer's Disease: Role of CCL2.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Axons; Biomarkers; Chemokine CCL2; Cyclooxygenase 2; Disease Models, Animal; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Inflammation; Memory Disorders; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Nerve Degeneration; Reboxetine | 2019 |